Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to content

EU Parliament rejects Anti Counterfeit Treaty

The European Parliament has rejected the international Anti-Counterfeiting Trade Agreement (ACTA) put before it by the European Commission, which means that it cannot become law in the European Union (EU).

478 MEPs voted against the Treaty, 39 for and 165 abstained.Parliament's striking down of the agreement was welcomed by international aid agency Medecins Sans Frontieres (MSF), which argued that ACTA could have limited access to quality generic medicines.

"The way it was written, ACTA would have given an unfair advantage to patented medicines and restricted access to affordable generic medicines, to the detriment of patients and treatment providers alike," said Aziz urRehman, intellectual property adviser for the MSF Access Campaign.

MSF emphasises that it strongly supports efforts to ensure that generic medicines meet accepted international standards. However, it also says that ACTA's over-broad definition of "counterfeiting" and its excessive enforcement provisions left too much room for error. Legitimately-produced generic drugs could have been seized and detained, hindering access for people who rely on these medicines to survive, says the agency.

More information here.

×

EAHP Forum

All the EAHP team is working on providing a Forum that can help connect all the members in Conversations and Groups to talk about important matters for the European Hospital Pharmacist.

The Forum will be accessible for all the EAHP members, you don’t have to create a new account to browse and participate.

Conversations and groups

The Conversations will be moderated by our team to provide documents and relevant topics for the community.

The Groups will connect all members that share a category. Members who work on the same assocation, on the same hospital, that have the same role, etc.

Stay tuned for the realase of the forum. Soon on EAHP.